William C. Zamboni

10.3k total citations · 2 hit papers
202 papers, 8.0k citations indexed

About

William C. Zamboni is a scholar working on Oncology, Molecular Biology and Biomaterials. According to data from OpenAlex, William C. Zamboni has authored 202 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Oncology, 83 papers in Molecular Biology and 70 papers in Biomaterials. Recurrent topics in William C. Zamboni's work include Nanoparticle-Based Drug Delivery (70 papers), Cancer therapeutics and mechanisms (57 papers) and Lung Cancer Research Studies (34 papers). William C. Zamboni is often cited by papers focused on Nanoparticle-Based Drug Delivery (70 papers), Cancer therapeutics and mechanisms (57 papers) and Lung Cancer Research Studies (34 papers). William C. Zamboni collaborates with scholars based in United States, Netherlands and Israel. William C. Zamboni's co-authors include Piotr Grodzinski, Alberto Gabizón, Uma Prabhakar, Omid C. Farokhzad, Hiroshi Maeda, David C. Blakey, Simon T. Barry, Eva M. Sevick‐Muraca, Rakesh K. Jain and Clinton F. Stewart and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

In The Last Decade

William C. Zamboni

196 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

2013 1.2k citations William C. Zamboni et al. Cancer Research profile →
Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles

2011 461 citations Huali Wu, William C. Zamboni et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William C. Zamboni United States	46	3.3k	3.1k	2.4k	2.4k	1.0k	202	8.0k
Maria Kavallaris Australia	58	6.1k 1.9×	1.9k 0.6×	2.2k 0.9×	3.2k 1.3×	1.1k 1.0×	201	12.3k
Neil Desai United States	33	2.5k 0.8×	3.3k 1.1×	2.2k 0.9×	3.9k 1.6×	1.3k 1.2×	87	9.3k
Timo L.M. ten Hagen Netherlands	49	3.6k 1.1×	2.7k 0.9×	3.1k 1.3×	1.8k 0.8×	956 0.9×	212	8.8k
Ronit Satchi‐Fainaro Israel	54	3.3k 1.0×	1.9k 0.6×	2.6k 1.1×	1.4k 0.6×	463 0.4×	158	7.5k
Patrick Soon‐Shiong United States	37	2.2k 0.7×	1.5k 0.5×	1.2k 0.5×	2.8k 1.2×	782 0.8×	162	7.9k
Leonard W. Seymour United Kingdom	68	9.1k 2.8×	2.8k 0.9×	2.2k 0.9×	2.9k 1.2×	504 0.5×	254	14.5k
Marc Dellian Germany	30	3.1k 0.9×	1.9k 0.6×	2.1k 0.9×	1.1k 0.4×	708 0.7×	67	6.4k
Tamara Minko United States	57	6.4k 2.0×	6.0k 2.0×	3.7k 1.5×	1.4k 0.6×	1.5k 1.4×	140	13.6k
János Szebeni Hungary	53	3.8k 1.2×	3.6k 1.2×	2.0k 0.8×	631 0.3×	1.0k 1.0×	168	10.4k
Arun K. Iyer United States	49	4.4k 1.3×	3.6k 1.2×	3.2k 1.3×	1.8k 0.8×	740 0.7×	131	9.9k

Countries citing papers authored by William C. Zamboni

Since Specialization

Citations

This map shows the geographic impact of William C. Zamboni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William C. Zamboni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William C. Zamboni more than expected).

Fields of papers citing papers by William C. Zamboni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William C. Zamboni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William C. Zamboni. The network helps show where William C. Zamboni may publish in the future.

Co-authorship network of co-authors of William C. Zamboni

This figure shows the co-authorship network connecting the top 25 collaborators of William C. Zamboni. A scholar is included among the top collaborators of William C. Zamboni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William C. Zamboni. William C. Zamboni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Li, Andrew T. Lucas, Aaron S. Mansfield, et al.. (2025). Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer. Clinical and Translational Science. 18(3). e70178–e70178. 3 indexed citations

Ravandi, Farhad, Sravanti Rangaraju, Hagop M. Kantarjian, et al.. (2025). A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia. Blood Advances. 9(9). 2136–2143. 1 indexed citations

Patterson, Briony, Nikita Sinha, S. Craig Stocks, et al.. (2025). Associations between obesity and outcomes in pembrolizumab-treated endometrial cancer. Gynecologic Oncology. 204. 228–234.

Graham-Gurysh, Elizabeth G., et al.. (2025). Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapy. Journal of Controlled Release. 387. 114225–114225. 1 indexed citations

Graham-Gurysh, Elizabeth G., Kathryn M. Moore, Christopher J. Genito, et al.. (2025). Post-resection delivery of a TLR7/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice. Nature Communications. 16(1). 8603–8603.

Graham-Gurysh, Elizabeth G., Kathryn M. Moore, Allison N. Schorzman, et al.. (2020). Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma. ACS Applied Materials & Interfaces. 12(17). 19345–19356. 43 indexed citations

Song, Gina, Oscar Suzuki, Charlene Santos, et al.. (2016). Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains. Nanomedicine Nanotechnology Biology and Medicine. 12(7). 2007–2017. 10 indexed citations

Karginova, Olga, Marni B. Siegel, Amanda E.D. Van Swearingen, et al.. (2015). Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA -Mutated and BRCA –Wild-Type Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 14(4). 920–930. 53 indexed citations

Song, Gina, David B. Darr, Charlene Santos, et al.. (2014). Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models. Clinical Cancer Research. 20(23). 6083–6095. 85 indexed citations

10.

Usary, Jerry, Wei Zhao, David B. Darr, et al.. (2013). Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice. Clinical Cancer Research. 19(17). 4889–4899. 40 indexed citations

11.

Roberts, Patrick J., Jerry Usary, David B. Darr, et al.. (2012). Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models. Clinical Cancer Research. 18(19). 5290–5303. 107 indexed citations

12.

Wu, Huali, Ramesh K. Ramanathan, Beth A. Zamboni, et al.. (2011). Population Pharmacokinetics of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies. The Journal of Clinical Pharmacology. 52(2). 180–194. 30 indexed citations

13.

Zamboni, William C. & Keisuke Yoshino. (2010). DDS製品開発の最前線 Formulation and physiological factors affecting the pharmacokinetics and pharmacodynamics of liposomal anticancer agents. Drug Delivery System. 25(1). 58–70. 4 indexed citations

14.

Edwards, Robert P., et al.. (2007). Evaluation of body surface area (BSA) based dosing, age, and body composition as factors affecting the pharmacokinetic (PK) variability of STEALTH liposomal doxorubicin (Doxil). Molecular Cancer Therapeutics. 6. 8 indexed citations

15.

Akhavan, Ardavan, Georgi Guruli, Robert R. Bies, et al.. (2006). Endothelin Receptor A Blockade Enhances Taxane Effects in Prostate Cancer. Neoplasia. 8(9). 725–732. 37 indexed citations

16.

Strychor, Sandra, Julie L. Eiseman, Erin Joseph, et al.. (2006). Plasma, tissue and tumor disposition of STEALTH® liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenografts. Cancer Research. 66. 721–721. 3 indexed citations

17.

Florian, Jeffry, William C. Zamboni, Julie L. Eiseman, et al.. (2006). A physiologically-based pharmacokinetic (PBPK) model of docetaxel in SCID mice bearing SKOV3 human ovarian cancer xenografts. Cancer Research. 66. 730–730. 1 indexed citations

18.

Zamboni, William C., Douglas M. Potter, Ramesh K. Ramanathan, et al.. (2005). Allometric scaling of STEALTH® liposomal anticancer agents. Cancer Research. 65. 326–326. 4 indexed citations

19.

Thompson, Joyce, Charles B. Pratt, Clinton F. Stewart, et al.. (1998). Phase I study of DMP 840 in pediatric patients with refractory solid tumors. Investigational New Drugs. 16(1). 45–49. 14 indexed citations

20.

Tubergen, David G., Clinton F. Stewart, Charles B. Pratt, et al.. (1996). Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five-Day Course in Children with Refractory Solid Tumors. Journal of Pediatric Hematology/Oncology. 18(4). 352–361. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact